Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Molecularly targeted therapies using receptor inhibitors, small molecules or monoclonal antibodies are routinely applied in oncology. Verification of target expression should be mandatory prior to initiation of therapy, yet, determining the expression status is most challenging in recurrent glioblastoma (GBM) where most patients are not eligible fo...
Alternative Titles
Full title
Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e99b130087fc4b6e97a2e9d45fdb26e1
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e99b130087fc4b6e97a2e9d45fdb26e1
Other Identifiers
ISSN
1479-5876
E-ISSN
1479-5876
DOI
10.1186/s12967-019-1846-y
